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Abstract
In addition to the well-documented role in the kidney, the mineralocorticoid 
receptor (MR) has been recently identified in different “non-classical” target tissues, 
such as the brain, the heart, vasculature, macrophages/monocytes, and adipose tis-
sue. In this context, the MR is involved in adipocyte fundamental processes such as 
differentiation, autophagy, and adipokine secretion. Excessive activation of the MR 
contributes to metabolic derangements occurring in mice with obesity and metabolic 
syndrome. Interestingly, MR pharmacological blockade in murine models of obesity 
has led to protection from weight gain and adipocyte dysfunctions. Unfortunately, 
there is still a lack of knowledge on the metabolic effects of MR antagonists, and 
larger clinical studies are deemed necessary to clarify the metabolic role of MR 
blockade in humans. This review discusses the role of MR in adipose tissue, focus-
ing on regulation by MR of key cellular processes occurring in the adipocyte. The 
molecular pathways affected by MR activation or blockade in adipose tissue have 
been investigated only in part. Hence, more studies are necessary to get more insights 
in the role of aldosterone/MR in this “non-classical” target tissue and to better 
understand its potential implications in obesity and metabolic syndrome.
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1. Introduction
Mineralocorticoid receptor (MR) activity in the distal nephron plays a well-known 
role in salt homeostasis and blood pressure regulation [1]. Importantly, studies per-
formed since the late 1980s by different laboratories have revealed the presence of MR 
also in non renal tissues (i.e., heart, brain, adipose tissue (AT)) [2–4]. The discovery 
of expression of MR in adipocytes, cardiomyocytes, and vascular cells has promoted 
further research to investigate MR function in the pathophysiology of obesity [5–7], 
cardiovascular disease [8–10], and metabolic syndrome [11]. Both aldosterone and 
glucocorticoids are able to activate MR [12]. Expression of the enzyme 11b-hydroxys-
teroid dehydrogenase type 2 (11b-HSD2) favors MR activation by aldosterone in 
epithelial tissues, whereas in non-epithelial tissues (AT, cardiomyocyte), scarce 
expression of 11b-HSD2 suggests that MR is activated mainly by glucocorticoids [12]. 
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However, it is still controversial whether increased circulating levels of aldosterone 
observed in obesity, metabolic syndrome, and primary aldosteronism (PA) can 
activate MR in non-epithelial tissues [13] and, in particular, in the adipocyte where 
this transcription factor regulates differentiation and modulates oxidative stress and 
adipokine expression [6, 14, 15]. Notably, preclinical studies in murine models of obe-
sity suggest that MR blockade counteracts fat mass expansion and improves insulin 
sensitivity, indicating that pharmacological antagonism of MR may represent a valid 
approach to fight obesity [5, 6], even though human studies have not yet confirmed 
such anti-obesogenic effects for MR antagonists.
Although a deeper comprehension of MR function in the adipose cell, at a molecu-
lar level, requires further research, it appears clear right now that adipocyte-specific 
MR represents a topic of future research on AT dysfunctions and obesity.
This review examines the state of the art of research on adipocyte MR, describes 
AT function, and analyzes the contribution of altered function of MR in the patho-
physiology of obesity and metabolic syndrome.
2. Adipose organ function
Adipose tissue is composed of two distinct types of fat: white adipose tissue (WAT) 
and brown adipose tissue (BAT) with distinct morphology and function. Both types of 
fat affect whole-body metabolism.
The adipose organ represents a multi-depot organ consisting of subcutaneous 
and visceral fat depots with a marked cellular heterogeneity, containing adipo-
cytes, preadipocytes, endothelial cells, fibroblasts, and immune cells [16, 17]. The 
adipocyte is the most relevant cell type in the AT and mammals display at least two 
distinct types of adipocytes, characterized by diverse morphology and physiological 
function. White adipocytes are unilocular spherical cells with a peripheral flattened 
nucleus and a single large cytoplasmic lipid droplet. White adipocytes are cells 
specialized for storing energy in the form of triglycerides and display endocrine 
properties, being able to synthesize and release secretory proteins called “adipo-
kines” involved in regulation of whole-body energy metabolism [16, 17]. On the 
other hand, brown adipocytes display a round central nucleus and a high number 
of cytoplasmic lipid droplets and mitochondria. Mitochondria in brown adipocytes 
are characterized by the expression of uncoupling protein 1 (UCP1) which is the 
hallmark of the brown adipocyte. UCP1 is a unique protein which allows uncoupling 
of oxidative phosphorylation from ATP synthesis, leading to dissipation of chemical 
energy as heat (non-shivering thermogenesis) [18]. WAT has storage and secretory 
function and contains mainly white adipocytes. In the brown adipose tissue (BAT), 
with thermogenic function, the prevalent type of adipocyte is the brown adipocyte. 
BAT function is regulated by the sympathetic nervous system, and its thermogenic 
activity maintains body temperature in the presence of cold exposure or during post-
natal period [19]. Up until a few years ago, BAT function was considered relevant 
only in hibernating mammals and newborn humans, whereas adult humans were 
thought to lack BAT [20]. Notably, studies published in 2007 and 2009 performed 
using fluorodeoxyglucose positron-emission tomography (FDG PET) [21, 22] have 
revealed the presence of functional BAT also in healthy adult humans, detected as 
regions of increased tracer uptake [22, 23]. Human BAT has been detected in the 
supraclavicular and cervical regions, as well as in mediastinal, paravertebral, para-
aortic, and suprarenal regions [21]. Cold exposure results in BAT activation both in 
mice and humans [24, 25] with parallel increase in energy expenditure and reduced 
fat mass, thus suggesting that BAT activity enhancement may be considered a valid 
approach to fight obesity also in humans [26].
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3. Adipose tissue dysfunctions in obesity
Dysfunctional adipose tissue is characterized by enlarged size of the adipocyte, altered 
expression of adipokines, pro-inflammatory polarization of resident macrophages, and 
defective thermogenic capacity.
Altered metabolic regulation of AT leads to excessive WAT expansion through 
two possible mechanisms: increased cell number (hyperplasia) and/or increased 
cell size (hypertrophy) [27]. Deregulated enlargement of adipocyte size promotes 
macrophage recruitment within WAT, through production of chemokines such as 
MCP-1 and IL-8. Macrophage recruitment is also associated with changes in macro-
phage polarization toward a pro-inflammatory phenotype (M1), which contributes 
to insulin sensitivity alteration [28]. Increased content of immune cells such as 
CD8+ T cells and IFN-γ+T-helper type 1 cells, in the AT of obese subjects, may 
contribute to the low-grade chronic inflammation associated with obesity [29]. In 
the obese state, altered expansion of WAT is also accompanied by increased secre-
tion of pro-inflammatory adipokines, such as leptin, TNF-α, and IL-6, paralleled 
by a reduced secretion of anti-inflammatory and insulin-sensitizing adipokines, 
thus promoting obesity-related complications. As discussed above, preclinical and 
human studies suggest that enhanced activity of brown adipocytes by stimulating 
thermogenic function can protect against obesity and associated alterations in 
glucose metabolism and lipid profile [24, 30]. Importantly, reduced amounts of 
BAT have been observed in overweight and obese subjects, indicating that impair-
ment in brown adipocyte activity may favor AT dysfunctions [22]. Indeed, a recent 
study has shown that a specific single-nucleotide T to C variant in the FTO locus 
promotes obesity development through inactivation of genes involved in brown 
adipogenesis, further confirming the importance of the brown fat in counteracting 
AT metabolic alterations [31].
In the adipocyte, MR has a central role in signaling pathways regulating physiol-
ogy and pathophysiology of AT. Research on MR function in AT has been summa-
rized and discussed in the paragraphs below.
4. MR in adipogenesis
MR plays a key role in regulating adipogenesis. Overactivation of MR promotes adi-
pose tissue dysfunction. On the other hand, MR antagonism counteracts white adipocyte 
differentiation and promotes brown adipogenesis.
The role of MR has been studied in adipocyte cultures and in murine models 
of obesity. MR activity has been shown to promote expression of adipocyte mark-
ers and stimulate differentiation of 3T3-L1 adipose cell cultures (Figure 1) [14], 
whereas MR antagonism counteracts adipogenesis in 3T3-L1 cells as well as in pri-
mary human adipocytes [32, 33]. In accordance with these data, primary adipocyte 
cultures obtained from mice knockout for MR have shown impaired adipogenesis 
[34], as well as knockdown of MR in cultures of human preadipocytes represses dif-
ferentiation [32]. Altogether, these data show that MR impaired function represses 
white adipocyte differentiation. Notably, in vivo studies show increased expression 
of MR in adipose tissue of obese mice and humans, suggesting enhanced activity 
of this receptor in the obese state which may contribute to adipocyte dysfunctions 
[11]. Pharmacological MR antagonism in obese mice counteracts weight gain and 
excessive expansion of fat mass [5, 6] and, at a molecular level, prevents altered 
expression of adiponectin, PPAR-γ, and leptin [15] confirming that MR activity 
modulates expression of adipocyte marker genes and regulates AT function. Recent 
data by Feraco et al. have shown that adipocyte-specific MR-KO mice do not show 
Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine
4
changes in AT function or glucose tolerance, under both normal diet and high-fat 
diet (HFD), indicating a negligible role of MR in AT [35]. Nevertheless, these 
transgenic mice express a Cre-recombinase protein (adipoq-Cre) which removes 
MR only in mature adipose cells. This may indicate that MR activity is not required 
in mature adipose cells, suggesting that MR modulation may be crucial in regulating 
early stages of white adipogenesis.
Studies by Lombes and collaborators have shown that MR is expressed in brown 
adipocytes [36] where MR activation represses expression of UCP1 (Figure 1), 
which confers thermogenic function to BAT [37]. In accordance with these data, 
more recent studies by Caprio and colleagues revealed that MR blockade promotes 
brown adipogenesis in cultures of mouse primary preadipocytes derived from 
inguinal AT increasing expression of brown adipocyte markers such as PRDM16, 
CIDEA, and PPAR-γ coactivator 1α (PGC1-α) [5]. Moreover, mice upon pharmaco-
logical MR blockade showed upregulated expression of these markers in BAT, with 
a parallel increase in BAT activity, confirming the impact of MR function on brown 
adipocyte function also in vivo [5].
5. MR involvement in “browning” of adipose tissue
Appearance of brown-like (brite) adipocytes in murine WAT takes place upon cold 
exposure. In mice, treatment with MR antagonist has been shown to promote browning 
and protect against fat mass expansion.
White and brown adipocytes display distinct embryonic origin. White adipocytes 
are derived from myogenic factor 5 (myf5)-negative progenitors, whereas classical 
brown adipocytes (and skeletal muscle cells) are derived from myf5-positive precur-
sors [38]. In addition, studies by Spiegelman and collaborators have identified a third 
Figure 1. 
Involvement of MR in the pathophysiology of adipose tissue. MR overactivation results in detrimental effects 
on adipocyte metabolism. Upregulated activity of adipocyte MR promotes expression of enzymes involved in 
reactive oxygen species (ROS) production and pro-inflammatory adipokines such as TNF-α and IL-6. In the 
adipocyte, increased function of MR stimulates the autophagic flux which, in turn, promotes white adipocyte 
differentiation. Altogether, these effects lead to alterations of adipose tissue metabolism. MR activation also 
represses brown adipogenesis, reducing thermogenic capacity and favoring adipose tissue dysfunctions.
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type of adipocyte, termed “beige” (or “brite”), localized in murine WAT depots [39]. 
These “brown-like” adipocytes display classical brown adipocyte morphological and 
biochemical features (several cytoplasmic lipid droplets and high number of mito-
chondria), even if they are derived from myf5-negative precursors [26]. Importantly, 
β-adrenergic stimulation results in increased levels in UCP1 and uncoupled respira-
tion rate in beige adipocytes, leading to the acquisition of brown fat features by WAT 
[39], a process known as “browning,” and several preclinical studies have shown 
that browning protects mice against glucose and AT dysfunctions. Transgenic mice 
with fat tissue-specific overexpression of PRDM16, a transcriptional regulator 
involved in brown adipocyte development, displayed brite adipocyte formation in 
inguinal WAT. These mice also showed increased energy expenditure and improved 
glucose tolerance with high-fat feeding and parallel reduction in weight gain and 
fat mass [40]. Accordingly, another study showed that transgenic mice lacking 
PRDM16 in AT display defective browning, obesity, and insulin resistance, strongly 
indicating that brite adipocyte function, at least in mice, affects AT metabolism and 
whole-body energy expenditure [41]. Treatment of mice fed with HFD with the MR 
antagonists spironolactone (spiro) or drospirenone resulted in browning of white fat 
depots, reduced weight gain, and decreased fat mass expansion, as well as improved 
glucose tolerance [5]. In this study, transcriptional induction of a thermogenic gene 
program by MR antagonism was observed both in mice and in primary cultures of 
mouse adipocytes treated with spiro and drospirenone, indicating that MR blockade-
mediated browning is cell autonomous.
However, further studies are required to better understand the molecular 
mechanisms regulated by MR which affect the thermogenic gene program of brite 
adipocytes.
The negative causal link between MR signaling and browning of WAT has been 
confirmed by Pisani et al. with Task1 −/− mice lacking the TWIK-related acid-
sensitive K+ channel. These mice displayed increased WAT mass and impaired 
browning, as well as reduced BAT activity upon adrenergic stimulation. In brown 
adipocytes from Task1 −/− mice, MR antagonist treatment was able to rescue 
defective expression of UCP1, suggesting that the absence of Task1 activity can 
result in enhancement of MR function and subsequent downregulated expression 
of thermogenic genes [42].
6. Regulation of autophagy by MR in adipose cells
The process of autophagy has been shown to regulate white and brown adipogenesis. 
Modulation of MR activity regulates the autophagic flux which, in turn, affects white 
and brown adipocyte differentiation.
In the eukaryotic cells, autophagy regulates organelle and protein turnover 
maintaining cellular homeostasis and function [43]. Increased autophagic flux 
has been observed during adipocyte differentiation [44, 45]. Recent research has 
identified genes involved in autophagy regulation (atg). In particular, the role of 
atg5 and atg7 has been analyzed both in transgenic mice and in adipocyte cultures 
[45, 46]. Impaired adipose differentiation, i.e., altered morphology and decreased 
lipid droplet accumulation, has been observed in autophagy-related 5 (atg5)−/− 
mouse embryonic fibroblasts (MEFs), and, accordingly, newborn mice lacking 
atg5 display reduced fat mass [45]. Likewise, both 3T3-L1 preadipocytes lacking 
atg7 and atg7−/− MEFs display impaired adipogenesis, showing that also atg7 
affects adipocyte maturation [46, 47]. Interestingly, Singh et al. have analyzed the 
metabolic profile of atg7-knockout mice showing that these mice have reduced WAT 
amount, paralleled by increased interscapular BAT. Moreover, browning of WAT 
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has been also detected in atg7-KO mice. Indeed, WAT of atg7-KO mice displayed 
higher levels of UCP1 and PGC-1α, a master regulator of mitochondrial biogenesis, 
and higher levels of mitochondrial enzymes. Therefore, this study suggests that 
impaired autophagy leads to the formation of brite adipocytes in WAT. Recent 
data from Caprio and collaborators have shown that MR regulates the autophagic 
flux in murine adipocytes (Figure 1) [5]. Both in 3T3-L1 cells and primary murine 
adipocytes, aldosterone treatment increases autophagy, whereas MR blockade 
reduces the autophagic flux. In mice fed with HFD, pharmacological antagonism of 
MR leads to reduced AT autophagic flux inducing, in turn, browning of WAT. These 
data confirm the effects of impaired autophagy on browning of WAT observed in 
atg7-KO mice [46]. Evidence of a causal link between impairment in autophagy and 
induction of browning has been also demonstrated by treating murine adipocytes 
with either spiro or bafilomycin (autophagy inhibitor) or everolimus (autophagy 
activator) [5]. Both spiro and bafilomycin reduce autophagic flux with a concomi-
tant increase in UCP1 levels, which indicates brown conversion of the adipose cell. 
Cotreatment with everolimus prevented UCP1 increase induced by spiro, indicat-
ing that decrease of autophagy is required for brown adipose conversion, whereas 
autophagy activation inhibits such process [5].
7. Metabolic effects of MR antagonism on adipose tissue metabolism
Overactivity of adipocyte MR contributes to the development of adipose tissue 
dysfunctions. Pharmacological blockade of MR counteracts adipocyte oxidative stress and 
adipocyte hypertrophy, improving insulin sensitivity and stimulating BAT activity.
Preclinical evidence suggests that increased expression of MR plays a role in AT 
dysfunctions. Increased levels of MR transcript have been detected in AT of obese 
humans and mice [11]. Data by Jaisser and collaborators has shown that adipocyte-
specific MR overactivity leads to obesity and metabolic syndrome features in 
mice overexpressing MR in adipocytes (adipo-MROE mice) [11]. In particular, 
upregulated expression of MR in mouse adipocytes leads to increase in body 
weight and visceral AT hypertriglyceridemia, hypercholesterolemia, and impaired 
insulin response. Interestingly, in adipo-MROE mice, adipocyte area was increased 
and positively correlated with the MR expression in visceral AT. Hypertrophy of 
the adipocyte is a well-known feature of dysfunctional AT associated with local 
and systemic inflammation and impaired insulin sensitivity [48]. Accordingly, 
increased activity of MR promoted adipocyte hypertrophy associated with negative 
effects on glucose metabolism of adipo-MROE mice [11]. A recent study by Feraco 
et al. has investigated the effects of adipocyte-specific MR ablation on mouse AT 
and glucose metabolism. Mice lacking adipocyte MR (adipo-MRKO mice) do not 
show changes in fat mass, glucose, and lipid profile, suggesting that MR removal, at 
least in the mature adipocyte, does not alter AT function [35]. As discussed above, 
in adipo-MRKO mice the enzyme adipoq-Cre removes MR in mature adipocytes 
but does not alter MR function in preadipocytes, indicating that removal of MR 
in the early stages of adipogenesis may indeed affect AT and explain the metabolic 
effects of pharmacological blockade of MR observed in mice [5]. Accordingly with 
this hypothesis, treatment of preadipocyte cultures with MR antagonist represses 
differentiation [33].
Pharmacological antagonism of MR in obese mice protects against weight gain, 
fat mass expansion, and local inflammation [5, 6]. In the AT MR blockade coun-
teracts adipocyte size enlargement, reduces the expression of pro-inflammatory 
adipokines (Figure 1), and promotes adiponectin production. In addition, MR 
antagonism reduces the expression of enzymes involved in reactive oxygen species 
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(ROS) production and, in parallel, increases the expression of ROS-eliminating 
enzymes, leading to decreased oxidative stress [6]. Increased oxidative stress has 
been detected in AT of murine models of obesity (mice fed with HFD or ob/ob 
mice), and mitochondrial dysfunction associated with obesity can contribute to 
production of ROS leading to carbonylation and impaired function of proteins such 
as IRS, contributing to AT dysfunction and insulin resistance [49]. In accordance 
with this, pharmacological blockade of MR reduces oxidative stress and improves 
insulin resistance in obese mice [6]. As mentioned above, treatment of mice fed 
with HFD with MR antagonists counteracts fat mass expansion and promotes 
also browning of WAT associated with improved glucose homeostasis. Therefore, 
preclinical studies with MR antagonists suggest that MR blockade counteracts AT 
dysfunctions dampening inflammation and oxidative stress and favoring brite 
adipocyte formation, at least in mice.
An increase in circulating levels of aldosterone is frequently observed in obese 
subjects, and recent data by Huby et al. suggest that leptin can contribute to the 
elevation of aldosterone [50]. This study reveals that the adipokine leptin can 
increase adrenal expression of the aldosterone synthase and plasma aldosterone 
levels, supporting the presence of a cross talk between AT and adrenal gland. 
In fact, increased secretion of leptin from the AT of obese subjects can lead to 
upregulated production of aldosterone which, in turn, may activate MR function 
in the adipocyte, further promoting leptin expression, fat expansion, and oxidative 
stress. Thus, in obesity, adipocyte MR might be overactivated by high plasma levels 
of aldosterone which further reinforces the dysregulated function of AT. There 
are very few studies that have investigated the role of adipocyte MR in humans. 
Karashima et al. have reported that treatment with MR antagonists for 12 months 
in subjects with primary aldosteronism (PA) led to reduction in blood pressure and 
visceral fat mass without changes in subcutaneous AT HOMA-IR, or in lipid profile 
[51]. To date, there are no other studies describing any effect of MR antagonism on 
human WAT. On the other hand, a recent study has shown that treatment with spiro 
in healthy adult subjects increases BAT volume and activity [52], indicating that MR 
blockade results in BAT function enhancement also in humans. These data suggest 
that the increase in thermogenic activity of BAT by MR antagonist-based therapies 
may represent a valuable approach to treat obesity.
8. Conclusion
A number of studies have shown that MR regulates AT physiology and can also 
contribute to the pathophysiology of obesity. In the adipocyte, MR has been shown 
to modulate transcript levels of adipogenic transcription factors, adipokines, and 
enzymes involved in ROS production (Figure 1) and scavenging. Notably, in murine 
models of obesity, treatment with MR antagonist is capable of counteracting exces-
sive expansion, increased inflammation, and oxidative stress of AT. Moreover, in 
adipocyte cultures and obese mice, MR blockade can reduce the autophagic flux and 
promotes brown adipogenesis, upregulating BAT activity and inducing browning 
of WAT, a process that exerts favorable effects against glucose intolerance and AT 
dysfunction. Recent data have also shown that treatment with MR antagonist is able 
to enhance BAT activity in humans, further supporting the potential of MR antago-
nists as novel pharmacological agents in programs of metabolic rehabilitation for 
subjects with obesity and metabolic syndrome. However, the molecular mechanisms 
downstream MR, which mediate the mentioned effects on adipocyte function, are 
poorly known. Indeed, deeper understanding of the molecular pathways modulated 
by MR is necessary to design efficient therapies against AT dysfunctions and obesity.
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